抗TNF多价VHH抗体奥佐利珠单抗治疗类风湿关节炎患者的长期安全性与有效性
本研究整合分析OHZORA、NATSUZORA和HOSHIZORA三项试验,评估奥佐利珠单抗治疗类风湿关节炎的长期安全性与有效性。OHZORA和NATSUZORA共入组521例患者,其中401例进入HOSHIZORA长期扩展试验,279例完成治疗,平均治疗时长200周,总暴露1419.34人年。96.9%的患者出现至少1例不良事件,多为轻至中度,观察到1例死亡,长期给药未出现新的安全性问题,美国风湿病学会20%、50%、70%缓解率在试验期间维持。
要点
- 奥佐利珠单抗长期给药未发现新的安全性问题,不良事件多为轻至中度。
- 美国风湿病学会20%、50%、70%缓解率在长期治疗期间维持。
- 全部入组患者总暴露1419.34人年,平均治疗时长200周。
核心结论
- 本整合分析显示,类风湿关节炎患者长期接受奥佐利珠单抗给药未出现新的安全性问题,且疗效得以维持。
研究设计与样本
- 本研究为对OHZORA、NATSUZORA和HOSHIZORA三项试验的整合分析。
- 完成OHZORA试验(奥佐利珠单抗联合甲氨蝶呤)或NATSUZORA试验(不使用甲氨蝶呤)的患者有资格参加长期扩展HOSHIZORA试验。
- 安全性在安全性分析集中评估,计算每100人年的不良事件和特别关注不良事件发生率。
- 有效性分析包括疾病活动指数应答率和功能缓解。
主要发现
- OHZORA和NATSUZORA试验共入组521例患者,其中401例进入HOSHIZORA试验,279例完成长期扩展治疗。
- 全部入组患者平均治疗时长200周,总暴露1419.34人年。
- 96.9%的患者出现至少1例不良事件,多为轻至中度。
- 观察到1例死亡,但长期给药未出现明显不良事件,特别关注不良事件中未发现特定问题。
- 有效性评估显示,试验期间美国风湿病学会20%、50%、70%应答率维持。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to evaluate the long-term safety and efficacy profiles of ozoralizumab in patients with rheumatoid arthritis (RA) from the OHZORA, NATSUZORA and HOSHIZORA trials. METHODS: This study conducted an integrated analysis of the three trials. Patients who completed the OHZORA trial with concomitant treatment of ozoralizumab and methotrexate (MTX) or the NATSUZORA trial without MTX were eligible to participate in the long-term extension HOSHIZORA trial. Safety assessment was performed in the safety analysis set, and the incidence rate per 100 person-year (PY) was calculated for a summary of adverse events (AEs) and AEs of special interests (AESIs). The efficacy was analysed in terms of disease activity index response rates and functional remission. RESULTS: The OHZORA and NATSUZORA trials enrolled 521 patients, of whom 401 patients entered the HOSHIZORA trial and 279 completed the long-term extension treatment with a mean treatment duration of 200 weeks and total exposure of 1419.34 PY in all enrolled patients. Of the patients, 96.9% demonstrated ≥1 AEs, which is mostly mild to moderate. One death was observed, but no conspicuous AEs emerged and no specific concerns in AESIs were found through the long-term administration. The efficacy assessment revealed the maintained American College of Rheumatology response rates of 20%, 50%, and 70% during the trials. CONCLUSION: This integrated analysis revealed no new safety concerns, and the efficacy was maintained in patients with RA under long-term ozoralizumab administration. TRIAL REGISTRATION NUMBER: jRCT2080223971, jRCT2080223973, NCT04077567.
引用
- Tanaka Y, Miyazaki Y, Kawanishi M, et al. Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis. RMD Open. 2024. PMID: 39179257. doi:10.1136/rmdopen-2024-004480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。